Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05286567
Other study ID # RGRN-305-002
Secondary ID 2021-000881-13
Status Completed
Phase Phase 1
First received
Last updated
Start date September 1, 2021
Est. completion date August 29, 2022

Study information

Verified date January 2023
Source Aarhus University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a 16-week treatment, randomized, double-blind, proof-of-concept study designed to assess the safety and efficacy of RGRN-305 compared to placebo for use in future efficacy Phase 2 trials. Male or female subjects aged 18 years or older with moderate to severe hidradenitis suppurativa will be included in this study. Objectives are to determine the efficacy and safety of RGRN-305 in patients with moderate to severe hidradenitis supppurativa.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date August 29, 2022
Est. primary completion date August 29, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: Subjects will be eligible to be enrolled in the study if they meet all of the following criteria at the Screening and Baseline (Day 0) Visits, unless specified otherwise: 1. Men or women aged 18 years or older at the time of consent. 2. Subject has a history of onset of hidradenitis suppurativa for at least 6 months prior to Baseline (Day 0) Visit. 3. Subject has hidradenitis suppurativa with at least 5 inflammatory nodules or abscesses (total AN count) in at least 2 distinct anatomic areas, both at Screening and Baseline (Day 0) Visits. Furthermore, one additional inflammatory nodule must be present for collection of skin biopsies. 4. Subjects (women and men) involved in any sexual intercourse that could lead to pregnancy must agree to use an effective contraceptive method from at least 4 weeks before Baseline (Day 0) until at least 4 weeks after the last study product administration for the duration of the study. Effective contraceptive methods are: systemic hormonal contraceptives (oral contraceptive, patch, vaginal ring, injectables, or implants), intrauterine devices, vasectomy, or barrier methods of contraception in conjunction with spermicide. Hormonal contraceptives must be on a stable dose for at least 4 weeks before Baseline (Day 0). Note: Woman of non-childbearing potential are as follows: - Women who have had surgical sterilization (hysterectomy, bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal ligation). - Women = 60 years of age. - Women > 40 and < 60 years of age who have had a cessation of menses for at least 12 months and a follicle-stimulating hormone (FSH) test confirming non-childbearing potential (FSH = 40 mIU/mL) or cessation of menses for at least 24 months without FSH levels confirmed. Protocol RGRN-305 - Safety and Efficacy of RGRN-305 in HS Page 13 of 61 Protocol version 3.2: 13 September 2021 5. Women of childbearing potential must have a negative serum pregnancy test at screening and negative urine pregnancy test at Baseline (Day 0). 6. Subject must have negative tuberculosis (TB) infection tests. Subjects will be evaluated for latent TB infection with a purified protein derivative (PPD) test, T-spot test or a Quantiferon Gold test, and with a chest x-ray, if one has not been performed in the last 6 months. Subject who demonstrates evidence of latent TB infection (either PPD = 5 mm of induration or positive Quantiferon Gold or T-spot test, irrespective of Bacillus Calmette-Guérin (BCG) vaccination status and negative chest x-rays findings for active TB, or suspicious chest x-ray findings) will not be allowed to participate in the study. 7. Subject must be willing to participate and must be capable of giving informed consent, and the consent must be obtained prior to any study-related procedures. Exclusion Criteria: 1. Female subject who is breastfeeding, pregnant, or who is planning a pregnancy during the study. 2. Subject has a history of skin disease or presence of a skin condition that, in the opinion of the investigator, would interfere with the study assessments. 3. Subject is known to have immune deficiency or is immunocompromised. 4. Subject has a history of cancer or lymphoproliferative disease within 5 years prior to Baseline (Day 0). Subjects with successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix are not to be excluded. 5. Subject has had a major surgery within 8 weeks prior to Baseline (Day 0) or has a major surgery planned during the study. 6. Subject has any clinically significant medical condition including ongoing infections, or physical/laboratory/ECG/vital signs abnormality that would, in the opinion of the investigator, put the subject at undue risk or interfere with interpretation of study results. 7. Subject has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) values = 2 times the upper limit of normal (ULN) at Screening. 8. Subject has absolute neutrophil count = 1.5 X 109/L or platelet count = 100 X 109/L at Screening. 9. Subject has a history of clinically significant anemia or hemoglobin (Hgb) value = 10 g/dL (6.21 mmol/dL) at Screening. 10. Subject has a creatine clearance = 60 mL/min at Screening (calculated with Cockcroft-Gault formula). 11. Subject with positive results for hepatitis B surface antigens (HBsAg), anti-hepatitis B core antibodies (anti-HBc), hepatitis C virus (HCV), or human immunodeficiency virus (HIV). 12. Subject has a known or suspected allergy to RGRN-305 or any component of the investigational product. 13. Subject has a history of clinically significant drug or alcohol abuse in the last year prior to Baseline (Day 0) Visit. 14. Subject is currently receiving an investigational product or device or has received one within 4 weeks prior to Baseline (Day 0) Visit. 15. Subject has received a live attenuated vaccine within 4 weeks prior to Baseline (Day 0) Visit or plan to receive a live attenuated vaccine during the study and up to 1 month after the last study drug administration. 16. Subject has a history of an allergic reaction or significant sensitivity to lidocaine or other local anesthetics. 17. Subject has a history of hypertrophic scarring or keloid formation in scars or suture sites. 18. Known inability or unavailability of a subject to complete required study visits during study participation. 19. A psychiatric condition (e.g., suicidal ideation), chronic alcohol, or drug abuse problem, determined from the subject's medical history, which, in the opinion of the investigator, may pose a threat to subject compliance.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
RGRN-305
Heat shock protein 90 inhibitor
Placebo
Placebo (blinded)

Locations

Country Name City State
Denmark Aarhus University Hospital Aarhus

Sponsors (1)

Lead Sponsor Collaborator
Aarhus University Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of subjects achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR-50) score Week 16
Secondary Percentage of subjects with Hidradenitis Suppurativa Physician's Global Assessment (HS-PGA) scores of clear or minimal Week 2, 4, 8, 12, 14, 16, and 20.
Secondary Percentage of subjects achieving HiSCR-50, HiSCR-75, and HiSCR-90 Week 2, 4, 8, 12, 14, 16, and 20.
Secondary Changes from Baseline in the Dermatology Life Quality Index (DLQI) total score Minimum score: 0 (no effect at all on patient's life) Maximum score: 30 (extremely large effect on patient's life) Week 4, 8, 12, 16, and 20.
Secondary Changes from Baseline in the Pain Numerical Ranging score Minimum score: 0 (No pain) Maximum score: 10 (worst pain) Weeks 4, 8, 12, 16, and 20
Secondary Change and percent change from Baseline in lesion counts (abscess count, inflammatory nodule count, AN count, and draining tunnel count). Week 2, 4, 8, 12, 14, 16, and 20.
Secondary Change from Baseline in skin biomarkers Week 16.
Secondary Change from Baseline in blood biomarkers Week 4, 8, 12, and 16.
Secondary Incidence of treatment-emergent adverse events (TEAEs). Week 20
Secondary Incidence of related TEAEs. Week 20
See also
  Status Clinical Trial Phase
Completed NCT02904902 - Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa Phase 3
Completed NCT03628924 - A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) Phase 2
Not yet recruiting NCT05531747 - Replicative Stress in Hair Follicle Stem Cells and Pathogeny of Hidradenitis Suppurativa N/A
Recruiting NCT06028230 - A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Phase 2
Completed NCT03275870 - Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa Phase 1/Phase 2
Completed NCT03248531 - A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa. Phase 2
Withdrawn NCT04100083 - Spironolactone for Hidradenitis Suppurativa Phase 4
Completed NCT00329823 - Etanercept in Hidradenitis Suppurativa Phase 2
Recruiting NCT05710393 - Hidradenitis - an Analysis of Genetic Traits and Linkages in Families
Completed NCT04019041 - A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa Phase 2
Withdrawn NCT03929835 - Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa Phase 2
Terminated NCT04325607 - Negative Pressure Wound Therapy With Instillation for Treatment of Hidradenitis Suppurativa N/A
Terminated NCT03238469 - Microwave Ablation in Mild Axillary Hidradenitis Suppurativa N/A
Completed NCT04449354 - HidraWear AX HS Study N/A
Recruiting NCT06123429 - Mindfulness in Hidradenitis Suppurativa N/A
Recruiting NCT05934825 - Clinical Trial to Evaluate Safety and Efficiency of Mesenchymal Stem Cell in Patients With Hidradenitis Suppurativa Phase 1/Phase 2
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Recruiting NCT06046729 - A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Phase 2
Recruiting NCT04246372 - Tofacitinib for Immune Skin Conditions in Down Syndrome Phase 2
Completed NCT01516749 - Anakinra as a Treatment for Hydradenitis Suppurativa Phase 2